Active ingredientVecabrutinibCat. No. P-V022-001CAS 1510829-06-7Family · Pharmaceutical analytical standards
Vecabrutinib
A reversible, non-covalent inhibitor of Bruton's tyrosine kinase (BTK), also active on the form of the enzyme mutated at C481. Studied in B-cell cancers such as chronic lymphocytic leukaemia, it stopped at phase Ib in 2020. This family brings together the active ingredient and labelled standards.
Did you know?BTK, and with it the -brutinib suffix, is named after the American paediatrician Ogden Bruton, who first described X-linked agammaglobulinaemia in 1952.
Go to the active ingredient →Active ingredientVecabrutinibCat. No. P-V022-001CAS 1510829-06-7
Isotopically labelledVecabrutinib-d4Cat. No. P-V022-002No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.